Kestra Medical secures up to USD 200 million five-year term loan facility with Pharmakon Advisors-managed funds

• Kestra Medical Technologies entered a five-year term loan facility with funds managed by Pharmakon Advisors for up to USD 200 million.
• USD 75 million funded at closing; part used to retire an existing USD 45 million term loan.
• Additional tranches total USD 125 million through 2028, including a USD 50 million tranche tied to USD 150 million trailing revenue.
• Interest-only payments for 48 months, extendable by 12 months on a revenue milestone.
• Quarterly interest rate set at 3-month SOFR + 5.5%, with a 3.25% SOFR floor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kestra Medical Technologies Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607141605PRIMZONEFULLFEED9761991) on July 14, 2026, and is solely responsible for the information contained therein.